Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says - 2Kennedy approves adding two rare disorders to newborn screenings
- 3Figure out How to Augment the Advantages of a Web-based Degree
- 4A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- 5Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Fake new headlights rule steer Australian drivers astray
- A hunger for new experiences Narratives: Motivating Travel and Experience
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- Major railway disruptions persist as Germany braces for more snow
- A Manual for Nations to Head out To
- The Significance of Prenuptial Arrangements in Separation Procedures
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
